{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:17:44Z","timestamp":1777969064980,"version":"3.51.4"},"reference-count":46,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15553","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:03:22Z","timestamp":1774616602000},"page":"1-13","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy\u2011based treatment patterns and clinical outcomes across lines of therapy in microsatellite stable metastatic colorectal cancer: A real\u2011world study"],"prefix":"10.3892","volume":"31","author":[{"given":"Wen-Si","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Jing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Dong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"key20260505102858_b1-ol-31-5-15553","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20260505102858_b2-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S2468-1253(23)00366-7","article-title":"Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: A population-based systematic analysis of GLOBOCAN","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20260505102858_b3-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM200001133420201","article-title":"Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer","volume":"342","author":"Gryfe","year":"2000","journal-title":"N Engl J Med"},{"key":"key20260505102858_b4-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"key20260505102858_b5-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"103669","DOI":"10.1016\/j.drudis.2023.103669","article-title":"Immunotherapy and immunoevasion of colorectal cancer","volume":"28","author":"Al Zein","year":"2023","journal-title":"Drug Discov Today"},{"key":"key20260505102858_b6-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b7-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","article-title":"Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): A Single-arm, Open-label, phase II trial","volume":"27","author":"Cousin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20260505102858_b8-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"S4028","DOI":"10.1200\/JCO.2020.38.15_suppl.4028","article-title":"Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China","volume":"38","author":"Gou","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b9-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.2023.41.4_suppl.150","article-title":"Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial","volume":"41","author":"Yuan","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b10-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: An open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"key20260505102858_b11-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: A randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"key20260505102858_b12-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20260505102858_b13-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"key20260505102858_b14-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1759-7714.13241","article-title":"Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody","volume":"11","author":"Fujita","year":"2020","journal-title":"Thorac Cancer"},{"key":"key20260505102858_b15-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.3390\/cancers15143564","article-title":"Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients' responders to a first course of ICI: A multicenter national retrospective study of the french group of skin cancers (Groupe de Cancerologie Cutanee, GCC)","volume":"15","author":"Nardin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20260505102858_b16-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.jhepr.2022.100620","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma","volume":"5","author":"Scheiner","year":"2023","journal-title":"JHEP Rep"},{"key":"key20260505102858_b17-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"e2428526","DOI":"10.1001\/jamanetworkopen.2024.28526","article-title":"Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw Open"},{"key":"key20260505102858_b18-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1001\/jamaoncol.2020.2169","article-title":"Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma","volume":"6","author":"Ravi","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20260505102858_b19-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"851756","DOI":"10.3389\/fonc.2022.851756","article-title":"Fruquintinib in combination With PD-1 Inhibitors in patients with refractory Non-MSI-H\/pMMR metastatic colorectal cancer: A Real-World study in China","volume":"12","author":"Gou","year":"2022","journal-title":"Front Oncol"},{"key":"key20260505102858_b20-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/s41467-025-56748-3","article-title":"Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: A single-arm, open-label, phase II clinical trial","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"key20260505102858_b21-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260505102858_b22-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260505102858_b23-ol-31-5-15553","first-page":"372","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"key20260505102858_b24-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"key20260505102858_b25-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.3390\/cancers13246311","article-title":"Combined treatment with Immunotherapy-based strategies for MSS metastatic colorectal cancer","volume":"13","author":"Baraibar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260505102858_b26-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"S3509","DOI":"10.1200\/JCO.2022.40.16_suppl.3509","article-title":"Phase II study of nivolumab in combination with FOLFOXIRI\/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS\/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018)","volume":"40","author":"Damato","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b27-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.eclinm.2023.102123","article-title":"Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: An open-label, single-arm, phase II trial","volume":"62","author":"Fang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"key20260505102858_b28-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20260505102858_b29-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: Updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b30-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"e008409","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: Phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J Immunother Cancer"},{"key":"key20260505102858_b31-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260505102858_b32-ol-31-5-15553","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"Armaghany","year":"2012","journal-title":"Gastrointest Cancer Res"},{"key":"key20260505102858_b33-ol-31-5-15553","first-page":"5","article-title":"Tumor-Infiltrating lymphocytes, tumor mutational burden, and genetic alterations in microsatellite unstable, microsatellite stable, or mutant POLE\/POLD1 Colon Cancer","author":"Keshinro","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"key20260505102858_b34-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20260505102858_b35-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann Oncol"},{"key":"key20260505102858_b36-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20260505102858_b37-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b38-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"100748","DOI":"10.1016\/j.esmoop.2022.100748","article-title":"Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase II study","volume":"8","author":"Cardone","year":"2023","journal-title":"ESMO Open"},{"key":"key20260505102858_b39-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1200\/JCO.2024.42.16_suppl.3571","article-title":"Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multicenter, single-arm, phase 2 trial","volume":"42","author":"Zhao","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b40-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JCO.2021.39.15_suppl.3564","article-title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the colorectal cancer cohort","volume":"39","author":"Gomez-Roca","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b41-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1200\/JCO.2022.40.4_suppl.135","article-title":"Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient\/microsatellite stable (pMMR\/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results","volume":"40","author":"Saeed","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260505102858_b42-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"e2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: A randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key20260505102858_b43-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260505102858_b44-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death Receptor 1\/Programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key20260505102858_b45-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-022-00922-2","article-title":"Colorectal liver metastasis: Molecular mechanism and interventional therapy","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"key20260505102858_b46-ol-31-5-15553","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:29:04Z","timestamp":1777966144000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15553","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}